Terms: = Endocrine gland cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Prognosis
22 results:
1. The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib.
Sánchez-Fdez A; Matilla-Almazán S; Montero JC; Del Carmen S; Abad M; García-Alonso S; Bhattacharya S; Calar K; de la Puente P; Ocaña A; Pandiella A; Esparís-Ogando A
Clin Transl Med; 2023 Apr; 13(4):e1217. PubMed ID: 37029785
[TBL] [Abstract] [Full Text] [Related]
2. Robotic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: Analysis of surgical outcomes and long-term prognosis in a high-volume center.
Zhang XP; Xu S; Zhao ZM; Liu Q; Zhao GD; Hu MG; Tan XL; Liu R
Hepatobiliary Pancreat Dis Int; 2023 Apr; 22(2):140-146. PubMed ID: 36171169
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic Value, Immune Signature, and Molecular Mechanisms of the PHLDA Family in Pancreatic Adenocarcinoma.
Duan Y; Du Y; Gu Z; Zheng X; Wang C
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142223
[TBL] [Abstract] [Full Text] [Related]
4. Protein expression profiling identifies a prognostic model for ovarian cancer.
Xiong L; Tan J; Feng Y; Wang D; Liu X; Feng Y; Li S
BMC Womens Health; 2022 Jul; 22(1):292. PubMed ID: 35840928
[TBL] [Abstract] [Full Text] [Related]
5. KIF22 Promotes Development of Pancreatic cancer by Regulating the MEK/ERK/P21 Signaling Axis.
Zhang R; Ma L; Wei Y; Wei K; Song T; Du Z; Feng Z
Biomed Res Int; 2022; 2022():6000925. PubMed ID: 35578724
[TBL] [Abstract] [Full Text] [Related]
6. The Transcription Factor SLUG Uncouples Pancreatic cancer Progression from the RAF-mek1/2-ERK1/2 Pathway.
Bilal F; Arenas EJ; Pedersen K; Martínez-Sabadell A; Nabet B; Guruceaga E; Vicent S; Tabernero J; Macarulla T; Arribas J
Cancer Res; 2021 Jul; 81(14):3849-3861. PubMed ID: 33903121
[TBL] [Abstract] [Full Text] [Related]
7. lncRNA DUXAP8 inhibits papillary thyroid carcinoma cell apoptosis via sponging the miR‑20b‑5p/SOS1 axis.
Pang R; Yang S
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760128
[TBL] [Abstract] [Full Text] [Related]
8. GINS2 promotes EMT in pancreatic cancer via specifically stimulating ERK/MAPK signaling.
Huang L; Chen S; Fan H; Ji D; Chen C; Sheng W
Cancer Gene Ther; 2021 Aug; 28(7-8):839-849. PubMed ID: 32747685
[TBL] [Abstract] [Full Text] [Related]
9. FAM172A inhibits EMT in pancreatic cancer via ERK-MAPK signaling.
Chen Y; Liu P; Shen D; Liu H; Xu L; Wang J; Shen D; Sun H; Wu H
Biol Open; 2020 Feb; 9(2):. PubMed ID: 31988090
[TBL] [Abstract] [Full Text] [Related]
10. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
[TBL] [Abstract] [Full Text] [Related]
11. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid cancer.
Owen DH; Konda B; Sipos J; Liu T; Webb A; Ringel MD; Timmers CD; Shah MH
J Natl Compr Canc Netw; 2019 May; 17(5):409-413. PubMed ID: 31085763
[TBL] [Abstract] [Full Text] [Related]
12. Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC).
Er JL; Goh PN; Lee CY; Tan YJ; Hii LW; Mai CW; Chung FF; Leong CO
Apoptosis; 2018 Jun; 23(5-6):343-355. PubMed ID: 29740790
[TBL] [Abstract] [Full Text] [Related]
13. Molecular manipulation of keratin 8/18 intermediate filaments: modulators of FAS-mediated death signaling in human ovarian granulosa tumor cells.
Trisdale SK; Schwab NM; Hou X; Davis JS; Townson DH
J Ovarian Res; 2016 Feb; 9():8. PubMed ID: 26911253
[TBL] [Abstract] [Full Text] [Related]
14. Quercetin 3-O-glucoside suppresses epidermal growth factor-induced migration by inhibiting EGFR signaling in pancreatic cancer cells.
Lee J; Han SI; Yun JH; Kim JH
Tumour Biol; 2015 Dec; 36(12):9385-93. PubMed ID: 26109002
[TBL] [Abstract] [Full Text] [Related]
15. LIM-only protein FHL2 critically determines survival and radioresistance of pancreatic cancer cells.
Zienert E; Eke I; Aust D; Cordes N
Cancer Lett; 2015 Aug; 364(1):17-24. PubMed ID: 25917075
[TBL] [Abstract] [Full Text] [Related]
16. Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
Galic V; Coleman RL; Herzog TJ
Curr Cancer Drug Targets; 2013 Jul; 13(6):698-707. PubMed ID: 23675882
[TBL] [Abstract] [Full Text] [Related]
17. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy.
Ganly I; Ricarte Filho J; Eng S; Ghossein R; Morris LG; Liang Y; Socci N; Kannan K; Mo Q; Fagin JA; Chan TA
J Clin Endocrinol Metab; 2013 May; 98(5):E962-72. PubMed ID: 23543667
[TBL] [Abstract] [Full Text] [Related]
18. mek1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
[TBL] [Abstract] [Full Text] [Related]
19. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Tomek K; Wagner R; Varga F; Singer CF; Karlic H; Grunt TW
Mol Cancer Res; 2011 Dec; 9(12):1767-79. PubMed ID: 21970855
[TBL] [Abstract] [Full Text] [Related]
20. p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.
Siu MK; Chan HY; Kong DS; Wong ES; Wong OG; Ngan HY; Tam KF; Zhang H; Li Z; Chan QK; Tsao SW; Strömblad S; Cheung AN
Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18622-7. PubMed ID: 20926745
[TBL] [Abstract] [Full Text] [Related]
[Next]
